Global Lung Cancer Liquid Biopsy Market Size By Type (CTCs, CtDNA), By Application (Clinics, Hospitals), By Region, And Segment Forecasts, 2023 to 2032

lobal Lung Cancer Liquid Biopsy Market Report Description

The Global Lung Cancer Liquid Biopsy Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 6.8 billion by 2031, growing at a CAGR of 15.7% during the forecast period (2023-2031).

The rising global incidence of lung cancer, the growing preference for minimally invasive diagnostic techniques, and the need for early cancer detection are major factors fueling market growth. Liquid biopsy offers a non-invasive, accurate, and real-time approach for detecting genetic mutations and monitoring disease progression, making it a preferred alternative to traditional tissue biopsies.

Furthermore, advancements in next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis are enhancing diagnostic precision, thereby boosting the adoption of liquid biopsies in oncology care.

Drivers

✅ Increasing Lung Cancer Prevalence

Lung cancer remains one of the leading causes of cancer-related deaths globally. The demand for early and precise detection methods is accelerating, driving adoption of liquid biopsy tests for initial diagnosis and monitoring.

✅ Growing Preference for Minimally Invasive Diagnostics

Unlike conventional tissue biopsy, liquid biopsy is less invasive, reduces patient discomfort, and allows for repeat sampling. This approach enhances patient compliance and is increasingly being integrated into clinical workflows.

✅ Technological Advancements in Biomarker Detection

Next-generation sequencing (NGS), digital PCR, and advanced ctDNA profiling have improved sensitivity and specificity of lung cancer liquid biopsy tests, creating new opportunities for targeted therapies and personalized medicine.

Restraints

❌ Limited Clinical Validation and Regulatory Challenges

Despite rapid innovation, not all liquid biopsy tests have sufficient clinical validation for routine use, leading to hesitancy among healthcare providers. Regulatory hurdles also slow market expansion.

❌ High Cost of Advanced Liquid Biopsy Tests

Cutting-edge technologies for lung cancer diagnostics can be expensive, limiting accessibility in low- and middle-income countries.

Opportunities

💡 Integration with Precision Oncology

Liquid biopsy plays a pivotal role in precision medicine, enabling early detection of resistance mutations and monitoring therapy response. Its integration into treatment pathways will expand market opportunities.

💡 Rising Demand in Emerging Markets

Emerging economies in Asia-Pacific and Latin America are investing in cancer diagnostics infrastructure, opening new growth avenues for liquid biopsy providers.

💡 Expansion of Companion Diagnostics

Pharmaceutical companies increasingly rely on liquid biopsies to stratify patients for targeted lung cancer therapies, presenting lucrative partnerships for diagnostic companies.

Market by System Type Insights

Circulating Tumor DNA (ctDNA)-based tests dominated the market in 2023, owing to their high sensitivity in detecting genetic alterations such as EGFR, ALK, and KRAS mutations in lung cancer patients.

Circulating Tumor Cells (CTC)-based assays are also gaining traction for monitoring tumor burden and predicting therapy response, but ctDNA remains the preferred choice for clinical applications.

Market by End-Use Insights

Hospitals & Cancer Clinics accounted for the largest share in 2023 due to the rising adoption of liquid biopsy for diagnosis and treatment monitoring.

Research and Academic Institutions are expected to witness the fastest growth as R&D activities in biomarker discovery expand.

Market by Regional Insights

North America held the largest share in 2023 due to advanced healthcare infrastructure, high lung cancer prevalence, and strong presence of leading diagnostic companies.

Asia-Pacific is anticipated to grow at the highest CAGR, driven by rising awareness, government initiatives for early cancer screening, and increasing adoption of precision oncology.

Europe remains a significant market, with extensive use of liquid biopsy in clinical trials and cancer care programs.

Competitive Scenario

Key players in the Global Lung Cancer Liquid Biopsy Market include:

Guardant Health

Roche Diagnostics

Bio-Rad Laboratories

Thermo Fisher Scientific

Illumina, Inc.

QIAGEN

Foundation Medicine

Exact Sciences

Natera, Inc.

These companies are focusing on developing highly sensitive assays, strategic collaborations with pharmaceutical companies, and regulatory approvals to strengthen their global presence.

Recent developments include:

2024: Guardant Health launched an updated version of its Guardant360 CDx for lung cancer, offering expanded biomarker coverage.

2023: Roche Diagnostics partnered with leading oncology networks to integrate liquid biopsy into lung cancer treatment pathways.

2023: Illumina unveiled an enhanced NGS-based assay optimized for ctDNA analysis in non-small cell lung cancer (NSCLC).

Scope of Work – Global Lung Cancer Liquid Biopsy Market

Key Market Developments

2024: Natera received FDA clearance for its Signatera ctDNA test for early lung cancer detection and recurrence monitoring.

2023: Foundation Medicine collaborated with pharmaceutical firms to co-develop liquid biopsy-based companion diagnostics for targeted lung cancer therapies.

2023: Bio-Rad introduced a new droplet digital PCR platform improving mutation detection sensitivity in NSCLC patients.

FAQs

1. What is the current market size of the Global Lung Cancer Liquid Biopsy Market?

The market was valued at USD 2.1 billion in 2023.

2. What is the major growth driver of the Global Lung Cancer Liquid Biopsy Market?

The primary driver is the increasing incidence of lung cancer and the demand for minimally invasive, accurate diagnostic methods.

3. Which region is expected to dominate the market during the forecast period?

North America will continue to dominate, while Asia-Pacific will witness the highest growth rate.

4. Which segment accounted for the largest market share in 2023?

The ctDNA-based liquid biopsy segment held the largest share in 2023 due to its high clinical utility in lung cancer management.

5. Who are the key market players in the Global Lung Cancer Liquid Biopsy Market?

Key players include Guardant Health, Roche Diagnostics, Thermo Fisher Scientific, Illumina, and QIAGEN.

Would you like me to also create a visually formatted PDF/Word version of this report description for easy sharing? Or should I proceed with another similar report for a different cancer liquid biopsy segment (like breast or colorectal cancer)?